This afternoon, our COO Ingrid de Visser-Kamerling gave a presentation at The World Vaccine Congress about the advantages and impact of using Controlled Human Infection Models (CHIM) in vaccine development.
By integrating CHIM studies early in the clinical pathway, researchers gain valuable data already in Phase I, allowing them to quickly assess efficacy, identify areas for improvement, and accelerate follow-up funding opportunities.
In addition, CHIM studies are faster and more cost-effective compared to traditional clinical trial pathways, bringing us closer to safe and effective vaccines at unprecedented speed.